Compare AbCellera Biologics Inc (ABCL) vs American Express Co (AXP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs American Express Co — how do they compare? AbCellera Biologics Inc trades at $10.05 (market cap $2.99B), while American Express Co trades at $341.69 (market cap $230.15B). The key difference: American Express Co is far larger — about 77× AbCellera Biologics Inc's market cap, and American Express Co pays a 1.11% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AXP | |
|---|---|---|
Market Cap | $2.99B | $230.15B |
Sector | Health | Financials |
52-Week High | $9.76 | $384.82 |
52-Week Low | $2.78 | $292.27 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
AXP trades at $341.25, up 0.7% on the day, with a bullish technical signal and strong support at $339. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.07% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Buy with a $369.42 price target. News highlights Amex Ventures' AI investments and premium cardmember perks.
Outlook is positive given earnings momentum and strategic AI bets, but risks include rising debt levels and competitive pressure. The stock offers growth potential with a reasonable P/E of 20.68, though investors should watch for economic sensitivity in consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →
